Delivery Order SPE2DB25D3306-SPE2DB26FUAPE
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 180 mg/1.2 mL on-body injector units. This firm fixed-price, non-set-aside delivery order was awarded on September 9, 2025, with an ultimate completion date of September 30, 2025. The pharmaceutical product will be delivered to a location in Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 180 mg/1.2 mL on-body injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation, with a completion date of October 8, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $11,830 on September 8, 2025, for the supply of SKYRIZI 180 mg/1.2 ml on-body injectors. This firm fixed-price delivery order, with completion expected by September 29, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency awarded a delivery order valued at $11,830 to AmerisourceBergen Drug Corp for SKYRIZI 180 mg/1.2 ml on-body injectors on September 25, 2025, with an ultimate completion date of October 17, 2025. This is a firm fixed-price, non-set-aside contract with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded a $23,660 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 mL on-body injectors on October 16, 2025, with completion targeted for November 6, 2025. This firm fixed-price, competitively awarded contract involves pharmaceutical supply to support military and federal healthcare operations. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a $11,830 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors. The contract, which carries an ultimate completion date of September 29, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors valued at $11,830.00, with completion targeted for October 21, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The contract represents a continuation of pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 180 mg/1.2 ml on-body injectors, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors. The contract is a firm fixed-price delivery order with no set-aside designation, competitively awarded and scheduled for completion by October 14, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors valued at $11,830.00. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The contract is set to complete by September 18, 2025, with performance executed from AmerisourceBergen's Conshohocken, Pennsylvania headquarters. This delivery order...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB26FUAPEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 180 mg/1.2 ml on-body injectors. This firm fixed price contract, awarded on October 31, 2025, with an ultimate completion date of November 24, 2025, represents a non-competitive, non-set-aside procurement. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal government's medical supply needs within the military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical support vehicle valued through December 2026. As a prime pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen leverages this master contract to fulfill recurring and specialized pharmaceutical requirements across multiple therapeutic domains for the Defense Health Agency and other federal healthcare entities. The company's established presence and proven capability within the DLA supply chain, combined with its extensive portfolio of brand-name and generic medications, positions it as a key provider for military healthcare pharmaceutical needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 10/31/25 |